# Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

> **NCT00038532** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 24 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Amprenavir/ritonavir
- **DRUG:** Saquinavir/ritonavir
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT00038532
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 24 (—)
- **Last updated:** 2008-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038532, "Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00038532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*